Published in Expert Opin Ther Pat on March 01, 2016
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell (2009) 4.50
Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med (2005) 3.59
Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol (2007) 2.70
Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med (2006) 2.54
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood (2010) 2.14
Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost (2005) 1.92
Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood (2008) 1.89
A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood (2010) 1.83
Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost (2006) 1.74
Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost (2011) 1.61
The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost (2007) 1.60
Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood (2003) 1.55
Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol (2010) 1.52
Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost (2006) 1.49
FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost (2002) 1.49
A murine model of factor XI deficiency. Blood Coagul Fibrinolysis (1997) 1.49
Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol (2007) 1.47
Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants. Thromb Res (2015) 1.43
Structure and function of factor XI. Blood (2010) 1.37
Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol (2013) 1.30
Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program (2013) 1.29
Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood (2012) 1.15
Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol (2014) 1.11
Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics (2013) 1.10
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood (2014) 1.05
Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost (2010) 1.04
Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors. Acta Crystallogr D Biol Crystallogr (2005) 1.04
Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol (2009) 1.03
Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa. J Med Chem (2008) 0.99
Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J Med Chem (2013) 0.97
Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med (2009) 0.96
Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Biochemistry (2009) 0.96
Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2014) 0.96
Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. J Med Chem (2006) 0.94
Localization of a heparin binding site in the catalytic domain of factor XIa. Biochemistry (2001) 0.93
Structural and functional features of factor XI. J Thromb Haemost (2009) 0.93
Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood (2012) 0.91
Simukunin from the salivary glands of the black fly Simulium vittatum inhibits enzymes that regulate clotting and inflammatory responses. PLoS One (2012) 0.91
Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site. J Med Chem (2013) 0.90
Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa. Bioorg Med Chem Lett (2006) 0.89
Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmacol Exp Ther (2003) 0.88
Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice. Transl Stroke Res (2012) 0.88
Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors. J Med Chem (2014) 0.87
Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo. Blood (2013) 0.87
Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol (2007) 0.87
Factor XI: hemostasis, thrombosis, and antithrombosis. Thromb Res (2011) 0.86
Design and synthesis of macrocyclic indoles targeting blood coagulation cascade Factor XIa. Bioorg Med Chem Lett (2010) 0.85
Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time. Thromb Res (2003) 0.85
A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis (2011) 0.84
Synthetic, non-saccharide, glycosaminoglycan mimetics selectively target colon cancer stem cells. ACS Chem Biol (2014) 0.83
Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model. Thromb Haemost (2013) 0.82
Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides. J Med Chem (2014) 0.81
Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis. Infect Immun (2011) 0.81
Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity. J Med Chem (2014) 0.81
High-resolution crystal structures of factor XIa coagulation factor in complex with nonbasic high-affinity synthetic inhibitors. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 0.79
Factor XI as a target for antithrombotic therapy. Drug Discov Today (2014) 0.79
Inhibition of Factor XI activity as a promising antithrombotic strategy. Drug Discov Today (2014) 0.78
Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design. PLoS One (2015) 0.77
Identification of an anticoagulant peptide that inhibits both fXIa and fVIIa/tissue factor from the blood-feeding nematode Ancylostoma caninum. Biochem Biophys Res Commun (2010) 0.76
Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis. Thromb Res (2010) 0.76
Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity. J Thromb Haemost (2014) 0.76
Next generation antithrombotic therapy: focus on antisense therapy against coagulation factor XI. Semin Thromb Hemost (2015) 0.76
Inhibitors of Factor XIa and Plasma Kallikrein May Treat Thromboembolic Disorders and Many Diabetes Complications. ACS Med Chem Lett (2014) 0.76
Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety. ACS Med Chem Lett (2015) 0.76